Nanocarrier-Based Approaches to Combat Chronic Obstructive Pulmonary Disease
- 20 July 2022
- journal article
- review article
- Published by Taylor & Francis in Nanomedicine
- Vol. 17 (24) , 1833-1854
Abstract
Abnormalities in airway mucus lead to chronic disorders in the pulmonary system such as asthma, fibrosis and chronic obstructive pulmonary disease (COPD). Among these, COPD is more prominent worldw...Keywords
This publication has 103 references indexed in Scilit:
- Pharmacotherapy of Chronic Obstructive Pulmonary Disease: A Clinical ReviewISRN Pulmonology, 2013
- Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluationsInternational Journal of Nanomedicine, 2011
- Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccinesJournal of Nanobiotechnology, 2011
- Evaluation of a Nanoemulsion-Based Formulation for Respiratory Delivery of Budesonide by NebulizersAAPS PharmSciTech, 2010
- Formulation strategy and use of excipients in pulmonary drug deliveryInternational Journal of Pharmaceutics, 2010
- Niosome: A future of targeted drug delivery systemsJournal of Advanced Pharmaceutical Technology & Research, 2010
- Lung Fibroblast Repair Functions in Patients with Chronic Obstructive Pulmonary Disease Are Altered by Multiple MechanismsAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary DiseaseProceedings of the American Thoracic Society, 2008
- Non-phospholipid vesicles for pulmonary glucocorticoid deliveryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2005
- Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectorsGene Therapy, 2001